Compare CORT & VMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | VMI |
|---|---|---|
| Founded | 1998 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.4B |
| IPO Year | 2001 | 1994 |
| Metric | CORT | VMI |
|---|---|---|
| Price | $81.34 | $421.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $141.00 | ★ $610.75 |
| AVG Volume (30 Days) | ★ 830.8K | 189.6K |
| Earning Date | 11-03-2026 | 10-20-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.09 | ★ 17.88 |
| Revenue | $761,407,000.00 | ★ $3,169,556,000.00 |
| Revenue This Year | $50.53 | $6.09 |
| Revenue Next Year | $46.23 | $7.43 |
| P/E Ratio | $954.56 | ★ $24.12 |
| Revenue Growth | 12.79 | ★ 14.52 |
| 52 Week Low | $28.66 | $378.02 |
| 52 Week High | $126.38 | $585.71 |
| Indicator | CORT | VMI |
|---|---|---|
| Relative Strength Index (RSI) | 22.77 | 29.18 |
| Support Level | $77.38 | $386.74 |
| Resistance Level | $122.93 | $421.11 |
| Average True Range (ATR) | 5.84 | 15.50 |
| MACD | -3.55 | -2.46 |
| Stochastic Oscillator | 0.71 | 1.10 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting, transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.